obesity

A central focus of the partnership is equipping family physicians and other healthcare professionals to better identify and support individuals at risk.

Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.

Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.

The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.

Pfizer secured marketing rights to the GLP-1 compound ecnoglutide through a partnership with Hangzhou-based Sciwind Biosciences announced last month.

The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.

The Department of Health – Abu Dhabi supported this groundbreaking investigation, which aligns with the emirate’s commitment to preventing diseases before they develop.

The plant is scheduled to begin operations by 2029 and will focus on producing cutting-edge treatments for metabolic conditions, particularly obesity medications.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.